Administrative data are often used as a proxy for medication-administration record (MAR) data. Multicenter MAR data were compared retrospectively with administrative data from January 2010 through June 2013 from the Pediatric Health Information Systems database. We found that administrative data were more concordant with bill-upon-administration than bill-upon-dispense data.
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The Centers for Disease Control and Prevention adopted days of antimicrobial therapy (DOT) as a process measure for healthcare facilities [1] . Hospital billing data are often used as a proxy for medication-administration record (MAR) data, which enables institutions to benchmark medication use [2, 3] . These administrative data sets not only span health systems, collaborative institutions, and government institutions but also are collected by private and government payers. Billing data for medications are extractable from the Pediatric Health Information Systems (PHIS) database, an administrative database that houses data from 42 freestanding pediatric centers and is commonly used for epidemiologic studies. This database has a history of providing data for studies of antimicrobial use [4, 5] . Although use of the PHIS to identify selected disease states has been validated, an assessment of its accuracy as a tool to describe actual drug administration has not been published [6] [7] [8] .
Because multiple pharmacy billing methodologies exist, billing data might not reflect drug administration across hospitals accurately. Some institutions bill when a medication is dispensed from the pharmacy or an automated dispensing cabinet, others bill when the medication is administered, and yet others use a combination of these approaches. Because not all dispensed doses are administered and multiple doses dispensed on separate dates could be credited in a single instance, days of therapy (DOT) metrics from the PHIS database have not traditionally subtracted dispensed doses that were not administered. This process might inflate DOT for institutions that bill upon dispensing. As more institutions implement electronic health records with medication-administration data, billing for medications upon administration becomes feasible. In this study, we sought to compare institutional MAR data with administrative data from the PHIS administrative database.
METHODS
We performed a multicenter retrospective review of aggregate MAR data from January 1, 2010, through June 30, 2013. Fortytwo freestanding children's hospitals contributed to the PHIS database at the time of this study. The study was approved or classified as not human-subjects research by the institutional review board of each of the 5 freestanding children's hospitals that participated in the study. Each of the 5 participating institutions created a deidentified aggregate set of MAR data for targeted antimicrobial agents. These data sets described the unadjusted number of DOT for these targeted antimicrobial agents, grouped according to route of administration (enteral or parenteral). DOT were defined as the documented receipt of any number of doses of a given antimicrobial per patient and per calendar day [3] . Data were limited to parenteral or enteral administrations of the following targeted antimicrobial agents: aminoglycosides, aminopenicillins, beta-lactamase combination products, carbapenems, cephalosporins, glycopeptides, echinocandins, fluoroquinolones, lincosamides, macrolides, monobactams, oxazolidinones, penicillinase-resistant penicillins, tetracyclines, triazoles, metronidazole, chloramphenicol, and colistimethate. These data sets were aggregated according to primary study site into monthly total DOT for each of the indicated antimicrobial agents and route of administration.
Once the MAR data set was produced, data for use of the same targeted antimicrobial agents during the same time period were extracted from the PHIS database. Administrators of the PHIS database track institutional data loads with known data-quality issues, which were excluded from analysis. One site had known data-quality issues during 2 months of the study period that arose from the acquisition of another hospital facility. Thus, these time points were removed from the analysis. In addition to the comparative data set, each site reported its current pharmacy billing practice and specified if it had changed during the study period. If the billing practice had changed, the sites were asked to identify the date of change. The answers to these questions then were used to categorize each data point as either MAR or dispense-based billing. A scatter plot with a linear regression of each billing type was generated to assess the concordance between PHIS administrative and MAR data using GraphPad Prism 4.03 for Windows (GraphPad Software, La Jolla, CA). A coefficient of determination was calculated for each model to assess the goodness of fit. To determine if other factors had an effect on the accuracy of data, ratios of aggregate total DOT from the PHIS and MAR data were calculated. These ratios were generated by billing type, route of administration, and antimicrobial class.
To assess the extent to which differences in billing modalities influenced the PHIS database, a survey was sent to antimicrobial stewardship practitioners at 38 institutions. Data collected included institution name, current billing practice, and if billing practices had changed within the 10 years before the survey. Responses were grouped to assess the proportion of institutions that billed upon dispensing and of those that billed upon administration in 2006 and 2016.
RESULTS
A total of 1 350 216 DOT were included in the MAR extracts from the 5 participating institutions. Only 2 of the 5 institutions used dispense-based pharmacy billing during the study period; each of them had converted to administration-based billing before July 1, 2012. The ratios of total PHIS/MAR DOT were 0.976 (998 683/1 012 740) for MAR-based billing and 1.235 (416 816/337 476) for dispense-based billing. No difference was found when we compared routes of administration for bill-upon-dispense data, and PHIS data were elevated for both enteral and parenteral routes over those of the MAR data. Enterally administered antimicrobial agents extracted from bill-upon-administration data were underrepresented with a ratio of 0.934 (211 352/226 234) compared to 0.988 (777 331/786 506) for parenterally administered medications from the same institutional time points. It is notable that the inflation of aminoglycoside DOT billed upon dispensing seemed to be higher than those of other classes of antimicrobial agents, with a ratio of 1.576 (33 672/21 364). No other differences were noted according to antimicrobial class in the dispense-or MAR-based data sets. The derived linear regression models shown in Figure 1 indicate that PHIS data better predict MAR charge data (0.9834x + 119.8 DOT; r 2 = 0.9795) than dispense charge data (0.3195x + 5831 DOT; r 2 = 0.4556). Of 38 institutions, 19 (50%) responded to the survey. Respondents reported that in 2006, only 10.5% (2 of 19) of the institutions were billing upon administration. This practice has shifted over time, with 73.7% (14 of 19) of institutions reporting that they were billing upon administration in 2016.
DISCUSSION
We found that medications billed upon administration are an optimal proxy for MAR data, which are considered the gold standard for measuring antimicrobial use. This result was reflected when PHIS data were plotted against MAR data. Although bill-upon-dispense data were inflated and had a weaker correlation with MAR data, we still found a strong correlation, which suggests that it might be possible to correct for the observed differences. The increasing proportion of institutions that bill upon administration will enhance the accuracy of PHIS data over time. As institutions adopt electronic medical record systems that use MAR data to bill, the integrity of billed doses should improve [9] . In addition to the greater accuracy of bill-upon-administration data, the adoption of barcode-assisted medication administration has decreased transcription errors and improved the quality of source data for administrative databases [10, 11] . As the PHIS database begins to incorporate clinical data beyond the MAR events analyzed here, the value of administrative data for a variety of benchmarking purposes will only continue to increase.
To gain further insight into the artificial inflation seen in bill-upon-dispense data, we subgrouped the data according to billing type, route of administration, and medication class. It was interesting that aminoglycosides had a larger difference between PHIS data and dispense-charged data than for other medications, which might be a result of the once-daily or less frequent dosing often seen in neonates and patients with cystic fibrosis. It is important to note that we observed that the dispense-based data were artificially elevated, because it is difficult to account for the return of medications from the medical ward to the pharmacy. The findings of this study do not indicate whether patients were billed for medications they did not receive but, rather, that there is no standard process for accounting for doses credited back to a patient's account when calculating DOT.
Although a discrepancy was found in bill-upon-dispense data submitted to the PHIS administrative database, it is unknown if similar data inflation would be seen in other administrative data sets. Also, this analysis did not include the assessment of patient census, which is often used as a denominator for antimicrobial use metrics, such as DOT per 1000 patient-days. The accuracy of census data was not investigated in this study, because we noted methodologic differences between departments within single institutions that can add complexity to such an analysis. Further analysis that incorporates hospital census data is important for validating the use of administrative data as a proxy for antimicrobial use normalized to census data within institutions. 
